News | Heart Failure | May 31, 2017

BioVentrix Announces Germany's First Revivent TC TransCatheter Ventricular Enhancement Procedure

Fifty-two-year-old patient suffering from ischemic heart failure showed 15 percent increase in ejection fraction following successful procedure

BioVentrix Announces Germany's First Revivent TC TransCatheter Ventricular Enhancement Procedure

May 31, 2017 — BioVentrix Inc. recently announced the first clinical use of its closed-chest Revivent TC TransCatheter Ventricular Enhancement System at the Deutsches Herzzentrum Berlin in Germany. The Less Invasive Ventricular Enhancement (LIVE) procedure was performed by interventional cardiologist Christoph Klein, M.D., and cardiothoracic surgeon Felix Hennig, M.D., with important contributions from Sebastian Kelle, M.D., chief of cardiovascular imaging.

The device was successfully implanted with two micro-anchor pairs in a 52-year-old male patient suffering from ischemic heart failure.  The procedure reshaped the left ventricle and decreased the left ventricular end systolic volume index (LVESVI). Left ventricular volume reduction is a common measure of cardiac performance that significantly impacts the short and long-term survival rates. By remodeling the LV to a more normal shape and size, the implant improves pumping efficiency, decreases wall stress and immediately reverses patient symptoms.

"We are impressed by the immediate impact of the less-invasive Revivent TC system," said Kelle. "The patient achieved a 33 percent reduction in LVESVI and a 15 percent increase in the ejection fraction," he continued.

"The therapy provides a much-needed option for patients suffering from heart failure due to left ventricular anterior scar, particularly when medical therapy is no longer effective. We are impressed by the immediate improvements and are eager to learn about the long term results of this promising method," said Klein.

"This patient's quality of life was severely impacted by his heart failure," said Hennig. "Especially for an older and more fragile population, the risks and recovery of surgery often preclude any meaningful intervention. The LIVE procedure eliminates the invasive elements associated with conventional surgical reconstruction. It expands the patient population that will be able to benefit from this procedure," continued Hennig.

For more information: www.bioventrix.com

Related Content

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement
News | Heart Failure | November 02, 2018
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the...
Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

News | Heart Failure | November 01, 2018
November 1, 2018 — Daxor Corp.
NHLBI Pauses CONCERT-HF Heart Failure Trial
News | Heart Failure | October 29, 2018
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is pausing the...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Cardiac Dimensions Randomizes First Patient in CARILLON Trial of Mitral Contour System
News | Heart Failure | September 20, 2018
Cardiac Dimensions announced the company has randomized its first patient in the CARILLON Pivotal Trial.
Overlay Init